Viracta Therapeutics, Inc. (NASDAQ:VIRX – Get Free Report)’s stock price fell 1.8% during trading on Thursday . The company traded as low as $0.47 and last traded at $0.48. 27,401 shares changed hands during trading, a decline of 75% from the average session volume of 107,935 shares. The stock had previously closed at $0.49.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on VIRX. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Viracta Therapeutics in a report on Tuesday, April 16th. Oppenheimer lowered their price objective on shares of Viracta Therapeutics from $13.00 to $11.00 and set an “outperform” rating for the company in a research report on Thursday, May 23rd.
Get Our Latest Research Report on Viracta Therapeutics
Viracta Therapeutics Trading Down 1.8 %
Viracta Therapeutics (NASDAQ:VIRX – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.12. Analysts predict that Viracta Therapeutics, Inc. will post -1.24 EPS for the current fiscal year.
Viracta Therapeutics Company Profile
Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.
Read More
- Five stocks we like better than Viracta Therapeutics
- Manufacturing Stocks Investing
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.